LAS VEGAS, NV, August 18, 2021 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, MSSV is pleased to announce that it has closed its acquisition of Global Stem Cells Group. “We are pleased to have finally been able to close on this acquisition,” said David Christensen, President and CEO of MSSV,” We are now well positioned to enter into the growing global Regenerative Medicine industry.”
Global Stem Cells Group (Global) is a premier Regenerative Medicine company that specializes in cutting edge stem cell research, current clinical applications, and physician training. Global licenses its intellectual property and name to medical professionals around the world providing them with necessary equipment and cellular therapy products needed to perform safe and effective Regenerative medicine related treatments. Global has one of the larges physician membership networks in the world with 29 offices in more than 25 countries. The worldwide Regenerative Medicine industry is a multi billion-dollar industry projected to have double digit annual growth rates over the next decade. For more information on Global Stem Cells Group please follow the link www.stemcellsgroup.com
Please read this press release in conjunction with the 8K that was filed today on www.sec.gov.
MSSV has also renegotiated its June 22, 2021 $10.5M financing, of which $8.2M is earmarked for the Lans Holdings Escrow as per the 8k filed June 24th, 2021, as follows: the warrant maturity has been changed to 7 years instead of 3 years and the warrant shall be locked up for the first 2 years whereas during the lock up period the warrant will not be able to be exercised.
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world. With the Company’s breadth of business experience and technology team, the Company will continue to help companies grow. Meso has now added bio-technology to it’s portfolio and will continue to grow the company in this new direction.
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world. With the Company’s breadth of business experience and technology team, the Company will continue to help companies grow.
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Meso Numismatics, Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Meso Numismatics, Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Telephone: (800) 956-3935
Cellgenic has worked closely with physicians all around the world for over a decade, and in working shoulder to shoulder with the rest of the medical community, we’ve gotten a feel for what we feel their main grievances are when incorporating regenerative medicine into their practice. We’ve found that primarily, the largest hurdles have been the large upfront costs, the long procedure times, and the difficulty procuring patients.
For a long time, most of the history of the nascent field of regenerative medicine, physicians would have to spend multiple thousands of dollars training themselves to use the procedures required to treat patients. In order to use this training, they would need to buy large, heavy, and expensive medical processing equipment in order to actually process the cellular samples. And after that, they would have to go through the trouble of procuring the enzymes and medical supplies needed to perform the procedure itself.
Every step of the process was mired with difficulty, and all of this was before even the patient acquisition process, which has the potential to completely make or break a practice. This is to not even mention the procedure itself, which can take anywhere from three to five hours of a physician being on their feet, and a patient being subdued under local anesthesia. The final result is an uncomfortable and drawn out procedure that regenerative medicine physicians have been working for years to optimize.
Cellgenic Exosomes is the company’s flagship product, which stands ready to revolutionize the practice of regenerative medicine as we know it today. Exosomes are extracellular vesicles which float freely within the blood, very much like platelets. But that is where the similarities end, because exosomes have been recently discovered to do far more than previously thought. Current science has identified them as one of the cornerstones of intercellular communication, as the enzymes that they secrete are responsible for cell-signalling, including calling healthy cells to begin the process of repairing damaged tissue. Because they consist of proteins, they are able to be administered without a risk of rejection from the patient, and they’re able to immediately get to work within the body, utilizing their growth factors and anti-scarring proteins to target inflammation and damaged tissue within the body.
Utilizing a potent combination of growth factors and anti-scarring proteins, they target inflammation and damage within the cells and tissues of the body and begin repairing it. The administration of Cellgenic Exosomes is simple. Every order arrives cryogenically-preserved under dry ice, and from there physicians can store them in the freezer for over one year. To administer, they simply need to be thawed out and injected into the patient, without the need for expensive and bulky equipment. All in all, this new process should not take more than forty-five minutes, and has lower upfront costs than the previous standard of care for regenerative medicine practitioners.
ISSCA has reopened its annual Regenerative Medicine Symposium for the Advancement of Cellular Therapies and Technology in Istanbul, Turkey.
MIAMI, FLORIDA , USA, May 31, 2021 /EINPresswire.com/ — After over a year of inactivity brought on by the COVID-19 pandemic, ISSCA has finally relaunched its annual Regenerative Medicine Symposium for the Advancement of Cellular Therapies and Technology in Istanbul, Turkey.
The world is finally beginning to once more open up to large gatherings of people. For the International Society for Stem Cell Applications, ISSCA, this has been a long time coming. The non-profit organization is renowned globally for bringing the benefits of regenerative medicine to countries around the world and fostering an international community of researchers through its conferences, the latest of which took place on May 27-28th at the Pullman Istanbul Hotel & Convention Center.
The symposium focused on bringing together doctors from all over the Middle East, as well as the world at large. During this event, physicians and researchers were given the opportunity to speak at panels to discuss the latest advancements in the rapidly growing field of regenerative medicine, chief among which were molecular biology, new models of treatment in surgical and cosmetic applications, and the latest technological advancements to hit the field. This includes a panel on Cellgenic Exosomes, which are the result of years of work towards finding a regenerative medicine product to cut down on strenuous operating room time. The proliferation of this information serves one purpose– the more effective treatment of patients suffering from degenerative disease around the world.
In addition to this, the conference also went over the legal landscape for the practice of regenerative medicine as it presents itself both in the United States (which is the model for many sovereign medical bodies) and abroad. Lectures were held throughout the day at this Symposium, which is part of ISSCA’s mission to support a paradigm shift from traditional healthcare solutions to regenerative medicine, and provide the latest innovative discoveries and developments in all areas of stem cell research.
Istanbul, the economic, cultural, and historic center of Turkey, is the country’s most populous city. The luxurious Hotel Hyatt Regency, located near Istanbul’s Ataturk Airport, offers visitors the combination of comfort, culture, and convenience for exploring the ancient city. Symposium attendees will be able to discover sights such as the Blue Mosque and the Hagia Sophia.
ISSCA Vice President Benito Novas had this to say about the conference: “It really feels amazing to be back out– after so long with lockdowns, and travelling difficulties, we were wondering if we would have to wait even longer to host an event. It’s been far from ideal– even if the world locks down, research continues, and new breakthroughs come through in our field of regenerative medicine month after month. Our ISSCA Symposiums provide a great opportunity to spread this information out to the physicians who need it the most, and we plan to host as many as we can before the end of the year,”
To participate in one of ISSCA’s upcoming events, reserve your spot by registering today.
For more information, visit our website at https://www.issca.us/, email email@example.com, or call +1305 560 5337.
About International Society for Stem Cells Applications
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
After several months of organizing and developing a location, the Global Stem Cells Group has finalized the construction of a laboratory and regenerative medicine research center in Uccle, Belgium.
This facility serves both as a regenerative medicine treatment and research center, but also as a plastic surgery clinic. In addition to this, one of the primary goals of the Center is to serve as a place for the fostering of knowledge and experience regarding the different products and equipment required for the application of cellular therapies. As part of the inaugural ceremony a group of physicians were trained in the setup and use of the various regenerative medicine protocols and application process of these cells into the patients.
This center is a push into Europe for the Global Stem Cells Group. As the science advances, newer and more advanced therapies and technologies are being developed and released into the market with each passing month.
With the European Union being one of the largest consumer markets in the world, the finalization of a brick-and-mortar location in Brussels, Belgium is one that will mean great things for the Global Stem Cells Group, and the presence and proliferation of regenerative medicine throughout Europe and the world.
“This was a wonderful opportunity that we could have. It goes to show that even during this pandemic, the medical community is one that is still going strong. We’re still rallying together to look for new breakthroughs, and come up with the most beneficial treatment options for patients,” Said Benito Novas, founder of the International Society for Stem Cell Applications, “In addition to this, it also provides an excellent platform for the distribution of regenerative medicine therapies and equipment, including the revolutionary new GCell Machine,”
Indeed, the inaugural training at the Stem Cell Center in Uccle, Belgium was one that covered both of the more traditional methods of stem cell isolation and application– adipose and bone-marrow derived autologous cells, but this training was also one of the first in which the company had the ability to demonstrate the novel GCell Machine. Using a precise system of blades and filters, it is able to process a stem cell sample from adipose tissue in less than half of the time that it would take a physician to do so through traditional means.
This allows the patient to be more comfortable throughout the shorter procedure, as less anesthesia is also required than when operating under traditional means. The GCell is a minimally invasive, portable machine that allows physicians to fully unlock the potential of regenerative medicine as a component in their practice. Using their global network of distributors and licensed vendors, Global Stem Cells Group is working fervently to ensure no interruption in the global availability of the most cutting-edge regenerative medicine products.
Stem Cells are revolutionizing the field of regenerative medicine, due to their intelligence. Once administered into the patient, they are able to identify and target areas of disease and damage. Adimarket’s Mesenchymal Stem Cell Product excretes growth factors, cytokines, and proteins, which all play a key role in the regeneration of tissue. Their anti-inflammatory and immunomodulatory properties mean that it is difficult for them to be rejected by the body. Additionally, they increase blood flow to the vital organs which need it the most.
Many proprietors of MSC products will claim that it is not necessarily important to have a high ratio of viable cells. They claim that it does not matter how many cells are ‘not viable’, or dead, so long as there is a high enough number of viable cells– however, current research has shown that this is not the case. These dead cells are detectable by the immune system, and it is believed that they can create an inflammatory response within the body at the treatment area, which would lower the effectiveness of the regenerative medicine treatments.
This bending of the science is harmful to our industry, which is why knowledgeable purveyors put one thing above all else– consistency. Our cellular concentrations are the same throughout each batch, and we make sure that there is a high ratio of viable cells. All of our samples are independently verified by a third party laboratory, and have been selected for their phenotypic and genotypic profile, characterized for optimum growth and stability. When the proper care is taken, Mesenchymal Stem Cell products have been identified as having the highest output of growth factors and stem cell factors among the current standards of care– as well as properties of angiogenesis, immunomodulation, and the potential for endogenous repair.
Cellgenic has been working for over a decade, constantly reinventing itself and reinforcing the products that we offer with the latest advancements in the field of regenerative medicine. We take every painstaking measure possible to ensure that the cellular samples that our customers use to treat their patients are second to none– this includes the consistent concentrations of our sample, which are the same throughout ensuring that every patient gets the same treatment. We offer the product in 10 million or 30 million live total nucleated cells, where other fabricators would have the same number of total cells. We ensure that every single product that we send out has been tested for low amounts of annexin, which is a cellular protein which serves as a marker for cell death.
All our Mesenchymal Stem Cell products come in 1cc vials cryogenically preserved– they are shipped overnight within the United States, conveniently delivered to your door in the morning. For use, the product is passively thawed between the palms of your hands– and ready to use when your patients are. MSC 10 contains 10 million live cells and is recommended for a single joint, or a small area. However, the MSC pure pro has 30 million live cells,and can be used for larger applications, or for up to three joints in the same patient at the same time.
If you are interested in finding out more about Cellgenic MSCs, you can send an eMail to firstname.lastname@example.org
The Global Stem Cells Group, a multi-disciplinary community of scientists and physicians that are collaborating to treat diseases and lessen human suffering through the advancement of the field of regenerative medicine has announced plans for a training in Brussels, Belgium on April 9/10th. This course is a long-awaited return to the country of Belgium after months of inactivity in the region brought about by the COVID-19 pandemic. During this time, research proceeded, and shocking discoveries were made that further thrust regenerative medicine into the world’s stage, and as a result the curriculum has been reinforced with the latest in IV therapy and exosome protocols.
This training will be one of the first of 2021, reaffirming the Global Stem Cells Group’s presence in Europe as a key player in the field of regenerative medicine. Members from both Global Stem Cells Group & the International Society for Stem Cell Application’s Brussels Chapter will be there to assist in expanding research for and the practice of regenerative medicine across Europe.
“It’s good to know that the Global pandemic has not been able to stop the progress of business,” Says Benito Novas, founder and CEO of the Global Stem Cells Group, “With reopening happening slowly, but surely, we hope that more and more physicians and clinics will take up the benefits of regenerative medicine.As we continue to train patients with the GCell Machine, ”
This training is intended to teach physicians the value and process behind incorporating regenerative medicine into their own clinical practice. This includes a theoretical portion that goes over basic regenerative medicine biology and its application, but also includes a Hands-On portion in which doctors, in a controlled environment and guided by a team of medical professionals, will have the opportunity to see procedures be performed just a few feet away, and then get the opportunity to try it for themselves.
The Belgium Stem Cell Center is one that is outfitted with the latest technology in regenerative medicine processing, which ensures any students that pass through it receive an education in extraction, isolation, and application of Platelet-Rich Plasma, Adipose, and Bone Marrow-Derived Mesenchymal Stem Cells.
This training will also teach physicians how to utilize the GCell Machine to perform regenerative medicine therapies. GCell is a tissue homogenization device that is revolutionizing the future of regenerative medicine. It is an extremely compact, all-in-one unit that can homogenize and isolate the stem cells from an adipose sample. GCell’s process of homogenizing with a system of precise blades and filtering ensures that the sample can be processed within an hour, with little input from the physician when the machine begins to do its work.
Once the process is over, the end result is a final product that can be administered to patients within an hour after the initial tissue extraction. This is a far cry from the previous, muti-hour long treatments that physicians have grown accustomed to, and the shortened timespan and simplicity of the procedure is something that both doctors and their patients will greatly appreciate.
If you are interested in enrolling in this upcoming event, or to learn more about the different training opportunities available, you can visit us at our training website.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop
hub for stem cell solutions that adhere to the highest medical standards.
As the newest field to regenerative medicine, it’s often exosomes therapy the least understood by those doctors newer to the field. While still not in use by many doctors, this is simply because it is new to the field. This is because many scientists are practically rabid to harnessthe benefits of this new treatment and apply them to target many of the conditions that modern medicine has allowed to slip through the cracks.
Extracellular Vesicles and Exosomes
The discovery of extracellular vesicles (EV), small bubbles composed of protein freely among cells, has been considered one of the greatest advancements in the field of medicine. They are broadly defined as something that exists outside of the cells of the human body, and they can be quite unique. Among these are exosomes, which has shown almost miraculous promise in treating inflammation, immunomodulation, cell-cell communication, and much more. Although it is certainly not a cure-all, it has been found to be good at what it does, which is almost a little bit of everything.This includes the communication and rejuvenation of all cells in the body, despite not actually being one itself.
Exosomes are created by growing a healthy stem cell culture and disposing of the cells themselves– this leaves behind the exosomes, millions of them, that were created in the process. Due to their microscopic size, what is left behind must be ultra-centrifuged, as it is the only way to concentrate them enough to use them on a patient. Despite all of their abilities, the makeup of exosomes is really quite simple, amino acids and RNA– this means that, aside from bearing immunomodulatory properties, it can also be applied to a patient without causing an immune system reaction. This is a worry that modern physicians must constantly think about when implanting foreign objects into patients, that is one of the great benefits of the use of exosome therapy.
An Overview on Exosome Therapy
Generally defined, exosome therapy is the use of exosomes in a clinical setting, a new step forward that is being happily taken by physicians worldwide. Exosome Therapy has very rapidly become one of the most popular fields of regenerative medicine treatment around the world. Painstaking research has managed to highlight the practical uses of exosomes, and how they can be used to treat conditions including lyme disease, hair loss, and arthritis. This is because, while stem cells are largely responsible for the rejuvenation of older cells, they might not be able to supply the information required for healing to take place– and this is where exosomes come in.
Consider exosomes the traffic conductors of regenerative medicine. They stimulate attention to damaged areas and work to control inflammation. In fact, many talented researchers believe that, by supporting the function of exosomes in the body, a better outcome could be obtained in patients. These scientific breakthroughs have fundamentally changed the healing process as we know it.
Exosome therapy is minimally invasive, and most commonly used in patients that present with orthopedic injuries, but this is not it’s only use. It shows great applications for anti-aging medicine, and the treatment of inflammatory and degenerative diseases. Exosome treatments generally contain a combination of growth factors, messenger RNA, micro RNA, and cytokines. The resulting exosome treatment is used in conjunction with stem cell therapies to boost the healing process in patients. These exosome therapies can be administered directly into the affected area, but they can also be administered through IV drip for those that are looking to make use of the anti-aging properties of exosomes.
Exosome injections are administered like other cellular therapies– administered directly into the part of the body affected by disease. In each case, patient dosing varies on condition and treatment plan, which means that there is no exact treatment protocol for exosome therapy. However, this allows physicians to fully customize them to a patient’s needs.
What can Exosomes Treat?
As the field of regenerative medicine constantly grows, more and more treatments are discovered every month! However, researchers have been able to offer exosomes as an exciting alternative for a wide variety of illnesses, including in arthritis therapy– it is believed to play a large role in bone and cartilage remodeling.Exosome therapy currently shows promise in treating the following conditions:
Hair Loss: Exosomes can be used to regrow hair due to their growth factor content. When injected exosomes trigger healing and the natural regeneration of hair follicles.
Lyme Disease: Exosomes may be beneficial to patients who suffer from Lyme disease, which is a very complex disease that compromises the immune system. Because it results in an increase in inflammatory responses, incorporating exosomes into one’s treatment plan could help break the cycle of inflammatory response.
Arthritis: Arthritis is known by many as the inflammation of the joints as a result of an autoimmune deficiency. Although various types of treatment are available to alleviate symptoms, nothing has been confirmed to reverse the disease’s progression.
Anti-Aging: Generally, aging can be thought of as a slow, steady inflammation of the body. Researchers have found a direct correlation between the number and types of exosomes within the body and the effects of aging, which means that exosome therapy could be used to reduce swelling in patients, and can be used to treat conditions such as crow’s feet, puffy eyes, and other markers of aging.
Pain Management: On a similar vein, many pain symptoms are also the result of inflammation– this is why certain over-the-counter medications allow for the treating of light pain. But for severe, chronic conditions that cannot be treated with over the counter options, exosome therapy could be the key to increasing their quality of life. By targeting the pained area at the source of inflammation, exosome therapy can increase quality of movement and reduce pain in certain orthopedic conditions including stress injuries.
As physicians around the world continue to study and apply exosomes, Global Stem Cells Group recognizes the fervent need to get these products into doctor’s hands. Our Cellgenic line has been in operation for years, helping physicians treat these conditions and more with exosome therapy.
Are you a physician that is currently utilizing adipose tissue, but is growing tired of the time-consuming, arduous procedure? Are you having problems finding reagents that allow you to isolate stem cells? If so, GCell might be the solution for you.
What is GCell?
GCell is a revolutionary new machine that holds the potential to become the future of adipose stem cell processing. This is due to a variety of reasons, from the compactness of the unit, to its short processing time– it truly is a valuable implement in any regenerative medicine practitioner’s office. GCell employs a process of mechanical breakdown, which in addition to shortening the duration of the treatment, also serves to keep it within legal minimal-manipulation regulations.
How Does GCell Work?
Through a system of extremely small blades and filters, it is able to homogenize a sample of fat taken from anywhere in the body, making it into a slurry of growth factors, proteins, and the other components that make up the sample. The GCell then filters out the stromal vascular fraction cells, and uses a process called photoactivation to increase their vitality. Once the process is over, the end result is a final product that can be administered to patients within forty minutes from the sample’s harvesting. This is a far cry from the previous, muti-hour long treatments that physicians have grown accustomed to, and this shortened timespan is something that both doctors and their patients will greatly appreciate.
Additionally, it is a single-session treatment. This means that patients that wish to receive a GCell treatment will only have to visit their clinic once, and will not have to undergo any followup treatments. This machine provides the convenience of its small size and lightweight build with the ability to accelerate the stem cell harvesting process– but that isn’t all. The GCell has been designed to be an entirely enclosed system– this is important, as it means that samples that are run through the GCell will remain in a sterile environment, which preserves the viability of samples and ensures positive outcomes for patients.
The GCell combines a grinder, a filter, and a photoactivation device, and is a turnkey solution that can take a physician from harvesting a fat sample to administering an injectable regenerative medicine therapy in less than an hour. GCell has been designed to be especially useful for clinics that are just beginning to implement regenerative medicine into their practice, but it’s all inclusive approach to stem cell isolation is what sets it a cut above the rest.
GCell’s Single Session Treatment Protocol
Unlike many other cellular therapies on the market, it is a single-session treatment, which means that there is no need for the patient to come back after his original treatment day has ended. This machine’s portability, small stature, and ability to accelerate the stem cell harvesting process makes it ideal for clinics that are just beginning to implement regenerative medicine into their practices, as it takes much of the rigor out of adipose-derived stem cell harvesting.
As the world continues to deal with the coronavirus, treatment options seem to be on everyone’s mind. There have been several studies regarding the use of umbilical cord-derived stem cells (and Mesenchymal Stem Cells in general), and the results have been trending upwards. As the field of regenerative medicine continues to advance, researchers such as those in the University of Miami continue to spearhead new and innovative ways of using regenerative medicine to treat a variety of conditions. These treatments, as their safety and efficacy grows, become important for both physicians and everyday individuals to be aware of, especially as they grow in availability.
One particular study, the one mentioned earlier conducted by researchers from the University of Miami, shows extremely promising results in the use of MSCs for the treatment of COVID-19.
While researchers first and foremost endeavored to verify whether this treatment was simply safe, they also ran tests in order to determine how useful it would be. The study was conducted among a group of twenty-four people, which were assigned at random to either control or treatment groups.
The results from the study seem to confer with what other researchers have discovered– in that stem cell therapies are entirely safe. Those patients that were administered 200 million MSCs were not seen to develop any adverse effects within the body, and patient survival was over twice as high in those treated with stem cells vs. those left untreated. Additionally, it was discovered that those that received the administration of cells also largely recovered within the first thirty days after receiving treatment at a greater rate than the placebo group.
This study and others like it highlight what practitioners of regenerative medicine have known through their own work for decades now– that Mesenchymal Stem Cells have the ability to target inflammation, regulate immune system function, and stimulate the recovery of cells. Global Stem Cells Group has been operating for years in these same treatments, treating patients around the world.
Through years of experience, and collaboration with expert researchers, Global Stem Cells Group, in partnership with Cellgenic, has developed cellular lines that have been used by physicians around the world in treating many conditions. For those interested in distributing or receiving treatment with regenerative medicine, or for further information, you can contact us by emailing email@example.com
[dzs_video source=” https://youtu.be/mjbFrl15jf4″ config=”skinauroradefault” autoplay=”off” cue=”off” loop=”off” type=”normal” responsive_ratio=”default”]
Just earlier this week, Global Stem Cells Group has signed a historic agreement with a company known as Bioscience Cell Factory– this Dubai-based healthcare company will allow GSCG to act as their representatives operating in both the Middle East and Latin America. Through the acquisition of proprietary branding rights Global Stem Cells Groups will become committed to promote the widespread use of cellular therapy treatments that utilize Mesenchymal Stem Cells (MSCs).
This partnership is groundbreaking in nature, and promises to lead to a wide proliferation of cellular therapies in both the Middle East and Latin America, two regions that are rapidly developing, with a constantly-advancing standard of medical care. Global Stem Cells Group will be clinically equipped with the highest standards and quality procedures as set forth by the Bioscience Cell Factory, resulting in nothing but the best treatment methods available for patients around the world.
“I’m extremely excited about this partnership,” Said Benito Novas, CEO of the Global Stem Cells Group, “Bioscience Cell Factory is one of the most professional and scientifically-focused teams that I’ve ever had the pleasure of working with– I am looking forward to the start of what will be an extremely beneficial professional relationship that will provide our global reach with the quality of Bioscience’s laboratory,”
Indeed, the two firms are also announcing plans to do research together into the nature of adult Mesenchymal Stem Cells, and the benefits that they hold for the medical field. Through the training of physicians and the handling of cell samples in their laboratory, there are high hopes for the advancement of the field of regenerative medicine research. As one of the representatives of the Bioscience Cell Factory abroad, Global Stem Cells Group will further its goal of being a global leader in the regenerative medicine field.
About Bioscience Cell Factory
Bioscience Clinic is a global healthcare company that is based in Dubai, committed to the running of a laboratory for the banking and use of all sorts of allogeneic and autologous cellular products. Through the proliferation of cellular therapies throughout the world, Bioscience Clinic hopes to advance treatment options for some debilitating diseases that current medical science has been largely unable to target the root causes of.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.